GSK has entered into a research collaboration with British biotechnology company Relation Therapeutics worth up to $110 million, expanding the companies’ existing work in AI-assisted drug discovery.
Under the agreement, Relation will generate large-scale datasets measuring how human cells respond to genetic changes and drug interventions. The data will be used to train AI models designed to identify potential drug targets, including models within Relation’s MORGAN platform.
The agreement places biological data generation alongside AI model development. Relation’s research approach links computational analysis with experiments that generate new…
Read the full article at ARTIFICIALINTELLIGENCE-NEWS.COM
